COMMITMENTS AND CONTINGENCIES (Details Narrative)
|
|
|
|
|
|
|
|
|
1 Months Ended |
12 Months Ended |
|
Aug. 16, 2022
USD ($)
$ / shares
shares
|
Dec. 31, 2021
USD ($)
|
Dec. 10, 2021
USD ($)
|
Jun. 10, 2021
ft²
|
Jan. 02, 2021
USD ($)
|
Sep. 24, 2020
USD ($)
$ / shares
|
Jul. 05, 2020
USD ($)
$ / shares
shares
|
Jun. 05, 2020
USD ($)
$ / shares
shares
|
Dec. 31, 2019 |
Mar. 31, 2018
USD ($)
|
Sep. 30, 2006
USD ($)
|
Sep. 30, 2022
USD ($)
shares
|
Sep. 30, 2021
USD ($)
shares
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options granted | shares |
|
|
|
|
|
|
|
|
|
|
|
1,901,410,519
|
|
| Stock options aggregate | shares |
|
|
|
|
|
|
|
|
|
|
|
1,901,410,519
|
|
| Consideration liability |
|
|
|
|
|
|
|
|
|
|
|
$ 78,440
|
$ 71,240
|
| Outstanding principal balance |
|
|
|
|
|
|
|
|
|
|
|
2,475,000
|
|
| Accrued interest payable |
|
|
|
|
|
|
|
|
|
|
|
38,440
|
31,240
|
| Litigation settlement number of shares | shares |
200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Litigation settlement shares, value |
$ 2,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Two Notes Payable [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding principal balance |
|
|
|
|
|
|
|
|
|
|
|
40,000
|
40,000
|
| Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss contingency damages sought value |
|
|
$ 100,000,000
|
|
|
|
|
|
|
|
|
|
|
| Busch Employment Agreement [Member]. | Restricted Stock Units (RSUs) [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accrued director compensation |
|
|
|
|
|
|
|
|
|
|
|
192,500
|
132,500
|
| Exclusive License Agreement [Member] | George Mason University [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty expense |
|
|
|
|
|
|
|
|
|
|
$ 50,000
|
|
|
| Revenue percentage |
|
|
|
|
|
|
|
|
|
|
1.50%
|
|
|
| Advance royalties |
|
|
|
|
|
|
|
|
|
|
|
2,443
|
1,591
|
| Exclusive License Agreement [Member] | Sublicense Royalty [Member] | George Mason University [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue percentage |
|
|
|
|
|
|
|
|
|
|
15.00%
|
|
|
| License Agreement [Member] | National Institutes of Health [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty expense |
|
|
|
|
|
|
|
|
|
$ 1,000
|
|
|
|
| Revenue percentage |
|
|
|
|
|
|
|
|
|
3.00%
|
|
|
|
| Advance royalties |
|
|
|
|
|
|
|
|
|
|
|
0
|
24,830
|
| Non refundable minimum annual royalty |
|
|
|
|
|
|
|
|
|
$ 5,000
|
|
|
|
| License Agreement [Member] | Sublicense Royalty [Member] | National Institutes of Health [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue percentage |
|
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
| Lease Agreements [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lessee operating lease description |
|
|
|
|
|
|
|
|
In
December 2019, the Company entered into a lease agreement for its corporate and laboratory facility in Golden, Colorado. The lease is
for a period of 61 months, with an option to extend, commencing in February 2020 and expiring in February 2025 (see Note 8)
|
|
|
|
|
| Lease period |
|
|
|
|
|
|
|
|
61 months
|
|
|
|
|
| Lease Amendment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rentable square feet | ft² |
|
|
|
4,734
|
|
|
|
|
|
|
|
|
|
| Monthly rent, description |
|
|
|
the Company must pay a total annual base rent of; (1) $115,823 for year one; (2) $119,310 for year two; (3) $122,893
for year three; (4) $126,580 for year four; (5) $130,377 for year five; (6) $135,163 for year six; (7) $139,218 for year seven; (8) $143,394
for year eight; (9) $147,696 for year nine; (10) $152,127 for year ten; (11) $156,331 for year eleven; (12) $161,391 for year twelve;
(13) $166,233 for year thirteen; (14) $171,220 for year fourteen and; (15) $176,357 for year fifteen
|
|
|
|
|
|
|
|
|
|
| Dr. Michael Ruxin [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Annual base salary |
|
|
|
|
|
|
|
|
|
|
|
112,500
|
62,500
|
| Dr. Michael Ruxin [Member] | Ruxin Employment Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Annual base salary |
|
|
|
|
|
|
|
$ 300,000
|
|
|
|
|
|
| Annual decretionary bonus percentage |
|
|
|
|
|
|
|
150.00%
|
|
|
|
|
|
| Dr. Michael Ruxin [Member] | Ruxin Employment Agreement [Member] | 2022 Equity Incentive Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted stock, shares | shares |
49,047,059
|
|
|
|
|
|
|
49,047,059
|
|
|
|
|
|
| Stock options granted | shares |
420,691,653
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options aggregate | shares |
469,738,712
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options exercise price | $ / shares |
$ 0.0036
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dr. Michael Ruxin [Member] | Ruxin Employment Agreement [Member] | 2022 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options granted | shares |
|
|
|
|
|
|
|
420,691,653
|
|
|
|
|
|
| Jeffrey Busch [Member] | Busch Employment Agreement [Member]. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Annual base salary |
|
|
|
|
|
|
|
$ 60,000
|
|
|
|
|
|
| Jeffrey Busch [Member] | Busch Employment Agreement [Member]. | 2020 Equity Incentive Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options exercise price | $ / shares |
|
|
|
|
|
|
|
$ 0.0036
|
|
|
|
|
|
| Jeffrey Busch [Member] | Busch Employment Agreement [Member]. | 2020 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options granted | shares |
420,691,653
|
|
|
|
|
|
|
420,691,653
|
|
|
|
|
|
| Jeffrey Busch [Member] | Busch Employment Agreement [Member]. | 2020 Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted stock, shares | shares |
49,047,059
|
|
|
|
|
|
|
49,047,059
|
|
|
|
|
|
| Stock options aggregate | shares |
|
|
|
|
|
|
|
469,738,712
|
|
|
|
|
|
| Thomas E Chilcott, III [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deferred compensation arrangements overall description |
|
The Board also approved two
new bonuses for which Mr. Chilcott will be eligible: (i) a $37,500 bonus payable upon the Company’s completion of a capital raise
of at least $1,000,000; and (ii) a $37,500 bonus payable upon the Company’s completion of a capital raise of at least $2,000,000
in the aggregate. During the year ended September 30, 2022, an aggregate bonus of $75,000 was paid to Mr. Chilcott.
|
|
|
|
|
|
|
|
|
|
|
|
| Thomas E Chilcott, III [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Annual base salary |
|
|
|
|
|
|
|
|
|
|
|
75,000
|
|
| Annual base salary |
|
$ 225,000
|
|
|
|
|
|
|
|
|
|
|
|
| Thomas E Chilcott, III [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Annual base salary |
|
$ 300,000
|
|
|
|
|
|
|
|
|
|
|
|
| Thomas E Chilcott, III [Member] | Offer Letter [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Annual base salary |
|
|
|
|
|
$ 225,000
|
|
|
|
|
|
|
|
| Stock options exercise price | $ / shares |
|
|
|
|
|
$ 0.0036
|
|
|
|
|
|
|
|
| Deferred compensation arrangements overall description |
|
|
|
|
|
Mr. Chilcott is entitled to participate
in all medical and other benefits that the Company has established for its employees. The offer letter also provides that Mr. Chilcott
will be granted an option to purchase up to 94,545,096 shares of the Company’s common stock which were granted on August 16, 2022
with an exercise price of $0.0036 and an expiration date of August 15, 2032 and subject to vesting terms.
|
|
|
|
|
|
|
|
| Consultant [Member] | Scientific Advisory Board Service Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compensation fees |
|
|
|
|
|
|
$ 2,000
|
|
|
|
|
|
|
| Payments for fees |
|
|
|
|
|
|
$ 1,500
|
|
|
|
|
|
|
| Consultant [Member] | Scientific Advisory Board Service Agreement [Member] | 2022 Equity Incentive Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options granted | shares |
|
|
|
|
|
|
88,786,943
|
|
|
|
|
|
|
| Stock options exercise price | $ / shares |
|
|
|
|
|
|
$ 0.0036
|
|
|
|
|
|
|
| Consultant [Member] | Pathology Advisory Board Service Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compensation fees |
|
|
|
|
|
|
$ 272
|
|
|
|
|
|
|
| Payments for fees |
|
|
|
|
|
|
$ 1,500
|
|
|
|
|
|
|
| Consultant [Member] | Pathology Advisory Board Service Agreement [Member] | 2022 Equity Incentive Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options granted | shares |
|
|
|
|
|
|
77,972,192
|
|
|
|
|
|
|
| Stock options exercise price | $ / shares |
|
|
|
|
|
|
$ 0.0036
|
|
|
|
|
|
|
| Mr. Kucharchuk [Member] | Consulting Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compensation fees |
|
|
|
|
$ 2,000
|
|
|
|
|
|
|
|
|
| Accrued consulting fees |
|
|
|
|
|
|
|
|
|
|
|
$ 12,000
|
$ 18,000
|